Cencora

404 articles about Cencora

• Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement

  11/22/2023

  Sapphiros is proud to announce it has entered into a distribution agreement with Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation.

• Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

  11/10/2023

  Cencora, Inc., formerly AmerisourceBergen Corporation, announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance’s entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended.

• Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results

  11/2/2023

  Cencora, Inc., formerly AmerisourceBergen Corporation, reported that in its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.

• Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release

  10/2/2023

  Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thursday, November 2, 2023, prior to the opening of trading on the New York Stock Exchange.

• AmerisourceBergen Announces Intent to Change Name to Cencora

  1/24/2023

  AmerisourceBergen (NYSE: ABC) today announced its intent to change its name to better reflect its bold vision and purpose-driven approach to creating healthier futures. AmerisourceBergen intends to become Cencora.

• AmerisourceBergen Kicks Off Strategic Relationship with Civica

  1/23/2023

  Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members.

• AmerisourceBergen Completes Acquisition of PharmaLex

  1/3/2023

  AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of its acquisition of PharmaLex Holding GmbH.

• AmerisourceBergen Announces Common Share Repurchase From Walgreens Boots Alliance

  12/9/2022

  AmerisourceBergen Corporation announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $200 million in concurrence with Walgreens Boots Alliance’s sale of AmerisourceBergen shares pursuant to Rule 144.

• AmerisourceBergen Elects Redonda Miller, M.D., to its Board of Directors

  11/16/2022

  AmerisourceBergen Corporation announced that its Board of Directors has elected Redonda Miller, M.D., 56, as a new independent director, effective January 1, 2023.

• AmerisourceBergen Announces Secondary Public Offering of Common Shares and Common Share Repurchase

  11/7/2022

  AmerisourceBergen Corporation announced a secondary public offering of 10 million shares of common stock of the Company held by Walgreens Boots Alliance Holdings LLC.

• AmerisourceBergen Reports Fiscal 2022 Fourth Quarter and Year End Results

  11/3/2022

  AmerisourceBergen Corporation reported that in its fiscal year 2022 fourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.

• 

  Opthalmology Space Gains Clarity with Partnerships & Acquisitions by Outlook & Visus Therapeutics

  9/28/2022

  A cloudy ophthalmic space got a little clearer Wednesday with the two collaborations by Visus Therapeutics and Outlook Therapeutics, now preparing for FDA approval.

• AmerisourceBergen Announces Date and Time for Fourth Quarter Fiscal 2022 Earnings Release

  9/28/2022

  AmerisourceBergen Announces Date and Time for Fourth Quarter Fiscal 2022 Earnings Release.

• AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors

  9/27/2022

  AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Lorence H. Kim, M.D., 48, as a new independent director, effective October 1, 2022.

• Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD

  9/27/2022

  Outlook Therapeutics, Inc. and AmerisourceBergen announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA).

• AmerisourceBergen to Expand Global Biopharma Services Platform With Acquisition of PharmaLex

  9/12/2022

  AmerisourceBergen Corporation (NYSE: ABC) today announced that it has signed a definitive agreement to acquire PharmaLex Holding GmbH, a leading provider of specialized services for the life sciences industry, from funds advised by AUCTUS Capital Partners AG for €1.28 billion in cash, subject to certain customary adjustments.

• AmerisourceBergen Hosts Inaugural Disparities in Cancer Care Summit

  8/12/2022

  AmerisourceBergen Hosts Inaugural Disparities in Cancer Care Summit.

• AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products

  7/27/2022

  As the pipeline of digital therapeutics (DTx) continues to expand, AmerisourceBergen today announced plans to launch DTx Connect.

• AmerisourceBergen Announces Date and Time for Third Quarter Fiscal 2022 Earnings Release

  6/29/2022

  AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2022 on Wednesday, August 3, 2022, prior to the opening of trading on the New York Stock Exchange.

• The AmerisourceBergen Foundation Commits $150,000 to Equitable Vaccination Efforts Across the Globe

  6/17/2022

  The AmerisourceBergen Foundation , an independent not-for-profit charitable giving organization focused on supporting health-related causes that enrich the global community, has committed $150,000 to the United Nations Foundation ’s Shot@Life campaign to support vaccine equity.